ArticleInternational journal of biological sciences2018
FGF23 and Fetuin-A Interaction in the Liver and in the Circulation.
Article in International journal of biological sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Enhanced Pneumonia Detection in Chest X-Rays Using Hybrid Convolutional and Vision Transformer Networks.Current medical imaging · 2025Article
- Osteokines in Nonalcoholic Fatty Liver Disease.Current obesity reports · 2024Review
- Severe hypophosphatemia induced by excessive production of FGF23 in acute hepatitis: from bedside to bench.Clinical kidney journal · 2024Article
- Associations of Intact and C-Terminal FGF23 with Inflammatory Markers in Older Patients Affected by Advanced Chronic Kidney Disease.Journal of clinical medicine · 2024Article
- Apigenin targets fetuin-A to ameliorate obesity-induced insulin resistance.International journal of biological sciences · 2024Article
- Is there a role in acute kidney injury for FGF23 and Klotho?Clinical kidney journal · 2023Review
- Metabolic Health and Disease: A Role of Osteokines?Calcified tissue international · 2023Review
- Can Serum Fetuin-A be Used as a Marker for Cardiovascular Involvement in Psoriatic Patients?Journal of psoriasis and psoriatic arthritis · 2023Article
- Effect of fetuin-A on adenine-induced chronic kidney disease model in male rats.Iranian journal of basic medical sciences · 2023Article
- The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects.Frontiers in endocrinology · 2023Review
- MCP1 Could Mediate FGF23 and Omega 6/Omega 3 Correlation Inversion in CKD.Journal of clinical medicine · 2022Article
- Vascular Calcification in Chronic Kidney Disease: An Update and Perspective.Aging and disease · 2022Article
- Fibroblast growth factor 23 level modulates the hepatocyte's alpha-2-HS-glycoprotein transcription through the inflammatory pathway TNFα/NFκB.Frontiers in medicine · 2022Article
- Fetuin-A, fibroblast growth factor 23 and inflammation in critically ill patients with sepsis.Metabolism open · 2021Article
- The Saga of Endocrine FGFs.Cells · 2021Review
- Myostatin regulates the production of fibroblast growth factor 23 (FGF23) in UMR106 osteoblast-like cells.Pflugers Archiv : European journal of physiology · 2021Article
- The Emerging Role of Innate Immunity in Chronic Kidney Diseases.International journal of molecular sciences · 2020Review
- Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently it has been demonstrated that Fetuin-A, an anti-inflammatory protein synthesized by the liver, is produced also in bone by an FGF23-regulated pathway. FGF23 has been also demonstrated to induce inflammatory cytokine production in the liver. This study aimed to explore if FGF23 plays a role in the Fetuin-A production in the liver cells too and the possible relationships with FGF23 pro-inflammatory effects. FGF23 and Fetuin-A were studied in liver, kidney and in plasma with immunochemistry, immunoprecipitation, western blot, chromatin immunoprecipitation, duolink, ELISA, qrtPCR methodology. FGF23 is produced, but not secreted by the liver cells. In hepatocytes and circulation, FGF23 was present only strictly linked to Fetuin-A, while Fetuin-A was found also in unbounded form. No link was observed in the kidney. FGF23 up to 600 pg/ml stimulates, while, at higher concentrations, reduces Fetuin-A expression. Notably, overall the range of concentrations, FGF23 stimulates Fetuin-A promoter, TNFα and IL6 expression. In the nucleus, FGF23 seems to act as a direct transcription factor of Fetuin-A promoter. These results suggest that FGF23 played a direct regulatory role in Fetuin-A expression in liver cells with a biphasic effect: Fetuin-A progressively increases when FGF23 increases up to 400-600 pg/mL, and declines at higher FGF23 concentrations. These results lead us to hypothesize: a) a possible epigenetic post-transcriptional regulation; b) a possible counter-regulatory effect of FGF23 induced inflammatory cytokines (TNFα/ NF-κB mechanism). This study could add an additional key for the interpretation of the possible mechanisms linking FGF23, Fetuin-A and inflammation in CKD patients and suggests a role for FGF23 as transcription factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.